radioimmunoconjugate

radioimmunoconjugate

(rād″ē-ō-im″yŭ-nō-kon′jŭ-găt, -im-ū″) [ radio- + immuno- + conjugate]
The chemical linkage of a monoclonal antibody to a radionuclide for therapeutic or diagnostic purposes.
Mentioned in ?
References in periodicals archive ?
M2 EQUITYBITES-October 19, 2016-Actinium Pharmaceuticals wins EMA orphan designation for radioimmunoconjugate Iomab-B
M2 PHARMA-October 19, 2016-Actinium Pharmaceuticals wins EMA orphan designation for radioimmunoconjugate Iomab-B
Another novel yet effective treatment is radio immunotherapy (RIT) which allows delivery of radiation to lymphoma cells using radioimmunoconjugates ([131]I- tositumomab and [90]Y-ibritutomomab tiuxetan have been approved till now) that target the CD20 antigen and are being used in the setting of recurrent follicular lymphoma setting.
Yttrium90, Iodine131, ibritumomab tiuxetan are the currently used radioimmunoconjugates.
Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates.
Future immunotherapy-based treatments will be enhanced by the radioimmunoconjugates and vaccine therapy.